An interventional study of percutaneous intramyocardial septal radiofrequency ablation system in Hypertrophic Obstructive Cardiomyopathy (HOCM), sponsored by SuZhou Sinus Medical Technologies Co.,Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-30.
Sponsored by SuZhou Sinus Medical Technologies Co.,Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Cardiomyopathy, Hypertrophic with a site in China — 31 open to participants now, 44 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · China.
Among the 72 studies in Cardiomyopathy, Hypertrophic with a site in China, this one is the 35th largest by enrollment of the 40 interventional ones that give a count, is one of 10 that started in 2024, is one of 20 with no phase, reaches primary completion later than 18 of the 43 other live ones, and was the 38th registered.
365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →31 of the 72 studies in Cardiomyopathy, Hypertrophic with a site in China are open now. Recruiting first, the newest first:
Ligang Ding · Sites in China
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18+
Bristol-Myers Squibb · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Ages 18–85 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 7 · Phase 4 3
First in 2011; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 60 across 182 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 83 across the 40 interventional studies, 608 across the 32 observational. Of the 21 that completed or were terminated, 5 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 72 have an industry lead sponsor. The 10 most frequent:
SuZhou Sinus Medical Technologies Co.,Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
SuZhou Sinus Medical Technologies Co.,Ltd has 2 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
9 of the studies in Cardiomyopathy, Hypertrophic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07354646Chinese Academy of Medical Sciences, Fuwai HospitalThe Application of T1 Mapping in Real-World | 2026-12-01 |
| NCT07006493SuZhou Sinus Medical Technologies Co.,LtdREFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy | 2026-12-30 |
| NCT07464132Peking Union Medical College HospitalApplication of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases | 2027-02-17 |
| NCT07846059Bristol-Myers SquibbEvaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy | 2027-03-31 |
| NCT06794710RenJi HospitalEarly Identification and Treatment of Rare Cardiomyopathy Cohorts | 2027-05-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 72 studies in Cardiomyopathy, Hypertrophic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hypertrophic cardiomyopathy (HCM) is a common clinical genetic-related disease, with a global incidence of 0.2%-0.5%, but only a few cases (10-20%) have been clinically diagnosed. About 70% of them are hypertrophic obstructive cardiomyopathy (HOCM), these HOCM patients have significant clinical symptoms, including progressively increasing fatigue, angina, exertional dyspnea, and syncope. Conservative medications are used to treat the vast majority of patients. Invasive therapy, which includes surgical myectomy, percutaneous transluminal septal myocardial ablation(PTSMA), percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) and percutaneous endocardial septal radiofrequency ablation (PESA) is introduced to patients with refractory symptoms or drug resistance. However, surgical operations are complicated and high risk procedures with high mortality. Interventional approaches are very difficult to perform and therefore the application is limited.
Previous researches have shown that interventricular septal radiofrequency ablation could effectively reduce the left ventricular outflow tract pressure gradient (LVOTG), thereby treating obstructive hypertrophic cardiomyopathy (HOCM). This device is based on the same radiofrequency ablation energy principle, however, the catheter is introduced into the right ventricle and performs ablation treatment on the hypertrophic interventricular septum, which is potentially a lower risk route of access for septal ablation than currently attempted interventional approaches.
The purpose of this study is to evaluate the safety and efficacy of percutaneous intramyocardial septal ablation catheters in the treatment of obstructive hypertrophic cardiomyopathy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: percutaneous intramyocardial septal radiofrequency ablation system
The device is introduced into the right ventricle and performs ablation treatment on the hypertrophic interventricular septum.
30-day major adverse clinical events (MACE)
30-day major adverse clinical events (MACE), including death, emergency surgery, severe pericardial effusion bleeding requiring pericardiocentesis or surgery, atrioventricular block, heart perforation, and surgery-related stroke.
Time frame: 30-day
Technical success rate
Technical success rate: the radiofrequency ablation catheter reaches the required treatment site, successfully completes the ablation, and is successfully withdrawn from the body.
Time frame: 30-day
Short Form 36 (SF-36) health survey questionnaire
The life quality score of SF-36 would significantly improved after the procedure. The higher scores mean a better outcome.
Time frame: 90-day
Improvement of left ventricular outflow tract gradient (LVOTG)
The improvement of LVOTG at post-procedure,30 days,3 months and 6 months after procedure. If the pressure gradient is reduced, the symptom will improve.
Time frame: 6 months
Improvement of NYHA functional classification
The improvement of NYHA functional class at post-procedure,30 days,3 months and 6 months after procedure. The lower class mean a better outcome.
Time frame: 6 months
6-min walk distance
The increase of 6-min walk distance at post-procedure,30 days,3 months and 6 months after procedure.
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Dec 2025, 21 months after the start.
Of 52 interventional studies with no phase under Cardiomyopathy, Hypertrophic, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiomyopathy, Hypertrophic →
SuZhou Sinus Medical Technologies Co.,Ltd